22 / 36
Time to CNS progression (by IRC, ITT)
Crizotinib
(N=151)
Alectinib
(N=152)
Patients with events, n (%)
68 (45)
18 (12)
Cause-specific HR
(95% CI)
P-value (log-rank test)
0.16
(0.10–0.28)
P<0.0001
Cumulative incidence of CNS progression
0
10
20
30
60
1
6
12
18
24
30
40
50
Crizotinib
12 month CIR:
41.4% (95% CI, 33.2–49.4)
Alectinib
12 month CIR:
9.4% (95% CI, 5.4–14.7)
Months
Cumulative Incidence (%)
S. Peters N Engl J Med 2017